Table 3.
Biochemical and immunologic properties of HLA-B*07;02-restricted and VACV-reactive CD8 T cell epitopes in B7.2 transgenic mice*
| Amino acid sequence** | ORF | t1/2 (hour) $ | Precursor frequency (#/mouse) | Magnitude of response to VACV % (mean)& | Magnitude of response to peptide % (mean)@ | Protective epitope% |
|---|---|---|---|---|---|---|
| LPRPDTRHL | A34R82–90 | 1.52 | 2465 | 4.0–10 (6.81) | 11.6–22.6 (15.0) | +++ |
| RPSTRNFFEL | D1R808–817 | 2.93 | 1892 | 4.0–8.7 (6.28) | 1.2–27.4 (13.9) | + |
| FPKNDFVSF | B8R70–79 | 5.2 | 1472 | 1.0–4.9 (2.38) | 16.6–51.5 (35.0) | +++ |
| MPAYIRNTL | J6R303–311 | 5.44 | 521 | 0.3–1.8 (0.86) | 11.9–51.4 (32.6) | +++ |
| HPRHYATVM | D1R686–694 | 6.47 | 308 | 0.2–1.6 (0.7) | 4.1–14.5 (10.1) | + |
| SPSNHHILL | A3L192–200 | 5.46 | 134 | 0.3–1.3 (0.67) | 14.4–34.5 (21.6) | +++ |
| FPTNTLTSI | I6L237–245 | 0.54 | nd | 0.01–0.8 (0.35) | nd | nd |
| FPRSMLSIF | L4R37–45 | 6.08 | 6104 | 0.05–0.3 (0.17) | 84.1–92 (86.5) | – |
| LPKEYSSEL | D5R375–383 | 7.44 | 1240 | 0.07–0.3 (0.16) | 8.3–22.6 (16.1) | +++ |
| APNPNRFVI | F4L6–14 | 8.81 | 668 | 0.03–0.5 (0.15) | 17.7–75.2 (53.6) | +++ |
| RPMSLRSTII | O1L335–344 | 5.31 | nd | 0–0.4 (0.14) | nd | nd |
| RPRDAIRFL | E2L216–224 | 4.81 | 126 | 0.03–0.2 (0.11) | 22.4–44.3 (24.5) | + |
| RPNQHHTIDL | N2L104–113 | 4.73 | nd | 0.02–0.3 (0.1) | nd | nd |
| FPYEGGKVF | E9L526–534 | 6.17 | nd | 0.01–0.1 (0.05) | nd | nd |
See Ref. [34 ] for details.
**
Listed in the order of hierarchy, see last column.
$
Half-life of p/MHC stability.
&
Range and mean of splenic responder CD8 T cells elicited by VACV infection.
@
Range and mean of splenic responder CD8 T cells elicited by peptide immunization; nd, not determined.
%
Protection from lethal intranasal VACV challenge of mice prime boosted with the test peptide:−, non-protective; + weakly protective — low burden yet sustained weight loss as compared to mock control; +++, highly protective — low VACV burden and weight loss when compared to control.